This webinar is for healthcare professionals only.
Prescribing information and adverse event reporting for ALUNBRIG ▼ (brigatinib), click here.
As part of both Takeda UK’s and LCNUK’s commitment to high quality medical education for the lung cancer nursing community, we are delighted to present the first in Takeda's series of 'let's tALK' promotional meetings, supported by LCNUK. The let’s tALK meeting series is an educational initiative committed to delivering topical, timely and high quality medical education to healthcare professionals specialising in the management and treatment of lung cancer. We are delighted to present the first recording in our series entitled ‘Optimising and managing the treatment of ALK+ aNSCLC’. The session was presented by Dr Yvonne Summers (Consultant Medical Oncologist) and Delyth McEntee (Clinical Nurse Specialist) both from The Christie NHS Foundation Trust, and it addressed the evolving landscape of treatment options in ALK+ disease, as well as the practical challenges involved in managing ALK patients on treatment.
Takeda UK, supported by LCNUK
- This promotional meeting was organised and funded by Takeda UK Ltd. and is for UK and Ireland healthcare professionals only.
- This meeting was supported by LCNUK.
- Takeda medicines were discussed during the meeting.
C-APROM/UKI/ALUN/0020 Date of preparation: February 2021